维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09887 维立志博-B

未开盘 02-03 16:08:20

66.150

+4.650

+7.56%

最高66.750	最低61.500	成交量57.24万
今开63.500	昨收61.500	日振幅8.54%
总市值131.64亿	流通市值101.21亿	总股本1.99亿
成交额3,693万	换手率0.37%	流通股本1.53亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"维立志博-B","latestPrice":66.15,"timestamp":1770106100010,"preClose":61.5,"halted":0,"volume":572400,"delay":0,"changeRate":0.07560975609756107,"floatShares":153000000,"shares":199000000,"eps":-2.008042,"marketStatus":"未开盘","change":4.65,"latestTime":"02-03 16:08:20","open":63.5,"high":66.75,"low":61.5,"amount":36934291,"amplitude":0.085366,"askPrice":66.5,"askSize":1300,"bidPrice":66.15,"bidSize":800,"shortable":3,"etf":0,"ttmEps":-1.583,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770168600000},"marketStatusCode":0,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":61.5,"openAndCloseTimeList":[[1770082200000,1770091200000],[1770094800000,1770105600000]],"volumeRatio":0.7670475102192139,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09887","defaultTab":"news","newsList":[{"id":"2608671006","title":"南京一药企产品获欧盟罕见病药物资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2608671006","media":"金台资讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608671006?lang=zh_cn&edition=full","pubTime":"2026-02-01 11:39","pubTimestamp":1769917156,"startTime":"0","endTime":"0","summary":"近日，南京江北新区生物医药谷企业维立志博宣布，其核心产品维利信已获欧盟委员会授予的罕见病药物资格认定，用于治疗肺外神经内分泌癌。罕见病药物，又称孤儿药。根据欧盟委员会的定义，孤儿药是指用于诊断、预防或治疗有生命危险或导致慢性衰弱疾病的药物，并且患者比例不超过欧盟人口总数的万分之五。维立志博首席医学官蔡胜利表示，本次获得欧盟孤儿药资格认定，标志着国际监管机构对公司技术平台及临床数据的再次认可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260201114230a46e4777&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260201114230a46e4777&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","HK0000500386.USD","BK1161","HK0000252160.HKD","HK0000252152.HKD"],"gpt_icon":0},{"id":"2607809556","title":"维立志博-B午后涨逾9% TCE双抗LBL-034获FDA快速通道资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2607809556","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607809556?lang=zh_cn&edition=full","pubTime":"2026-01-30 14:14","pubTimestamp":1769753640,"startTime":"0","endTime":"0","summary":"　　维立志博-B午后股价上涨8.78%，现报65.65港元，成交额5281.46万港元。　　维立志博宣布，1月27日，公司基于TCE技术平台LeadsBody自主研发的具有独特2：1结构和条件性激活的GPRC5D/CD3双特异性抗体LBL-034获得美国食品药品监督管理局授予快速通道资格认定，用于治疗复发/难治性多发性骨髓瘤。　　华福证券发布研报称，维立志博基于激动剂平台+TCE平台+ADC，全面布局下一代肿瘤免疫疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-01-30/doc-inhkakfh0203738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000252152.HKD","HK0000500386.USD","HK0000252160.HKD","09887","BK1161"],"gpt_icon":0},{"id":"2607056346","title":"每日卖空追踪 | 维立志博-B 01月29日卖空量成交3.33万股，卖空比例为8.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607056346","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607056346?lang=zh_cn&edition=full","pubTime":"2026-01-29 16:30","pubTimestamp":1769675444,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间01月29日，涨1.51%，卖空量成交3.33万股，较上一交易日减少5.67%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129164306a463ee94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129164306a463ee94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","HK0000252152.HKD","09887","HK0000252160.HKD","HK0000500386.USD"],"gpt_icon":0},{"id":"2607777506","title":"港股异动 | 维立志博-B(09887)再涨近6% TCE双抗LBL-034获FDA快速通道资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2607777506","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607777506?lang=zh_cn&edition=full","pubTime":"2026-01-29 10:59","pubTimestamp":1769655560,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B(09887)再涨近6%，截至发稿，涨4.63%，报62.2港元，成交额1142.28万港元。消息面上，维立志博宣布，公司基于专有TCE技术平台LeadsBody自主研发的GPRC5D/CD3双特异性抗体LBL-034，获得美国食品药品监督管理局（FDA）授予的快速通道资格认定，用于治疗复发/难治性多发性骨髓瘤（RRMM）。这是继2024年10月获FDA孤儿药认定后，该产品在国际化开发道路上的又一重要里程碑，标志着其临床价值与开发策略进一步获得国际监管机构的认可。据悉，LBL-034是一款靶向GPRC5D及CD3的人源化双特异性T细胞衔接器。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1398976.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000500386.USD","HK0000252160.HKD","BK1161","BK4588","09887","BK4585","VT","HK0000252152.HKD"],"gpt_icon":0},{"id":"2606754444","title":"维立志博-B(09887)：LBL-034(GPRC5D/CD3双特异性T-CELL ENGAGER，TCE)获美国FDA授予快速通道资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2606754444","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606754444?lang=zh_cn&edition=full","pubTime":"2026-01-28 08:38","pubTimestamp":1769560721,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，于2026年1月27日，LBL-034(GPRC5D/CD3双特异性抗体)获美国食品药品监督管理局(“FDA”)授予快速通道资格认定(“FTD”)，用于治疗复发╱难治性多发性骨髓瘤(“RRMM”)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1398303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维立志博-B(09887)：LBL-034(GPRC5D/CD3双特异性T-CELL ENGAGER，TCE)获美国FDA授予快速通道资格认定","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","HK0000252152.HKD","BK1161","HK0000500386.USD","HK0000252160.HKD"],"gpt_icon":0},{"id":"2606748735","title":"每日卖空追踪 | 维立志博-B 01月27日卖空量成交3.65万股，卖空比例为4.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606748735","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606748735?lang=zh_cn&edition=full","pubTime":"2026-01-27 16:30","pubTimestamp":1769502645,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间01月27日，涨3.89%，卖空量成交3.65万股，较上一交易日增加60.79%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127164320a6b23a9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127164320a6b23a9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD","09887","BK1161"],"gpt_icon":0},{"id":"2606272282","title":"华福证券：医药生物业新技术全面突破 战略看多中国创新出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2606272282","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606272282?lang=zh_cn&edition=full","pubTime":"2026-01-27 11:01","pubTimestamp":1769482871,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华福证券发布研报称，2025年中国创新药全球竞争力凸显，出海交易创新高，多家企业扭亏为盈。战略看多中国创新出海。华福证券主要观点如下：国内复盘：全球竞争力凸显，企业扭亏为盈+管线出海价值新高度2025创新药指数大涨，Biopharma和Biotech持仓比例显著提升，核心驱动因素是中国创新药全球竞争力凸显。创新药市场份额快速提升，肿瘤与免疫领域创新药份额超32%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127110355a6b10694&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127110355a6b10694&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01672","01801","HK0000165453.HKD","09606","06160","BK1583","09887","01276","BK1574","06955","09926","06938","BK1161","06978","02157","02162","01530","02615","02096","BK1593","01093"],"gpt_icon":0},{"id":"2606276635","title":"港股维立志博-B涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606276635","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606276635?lang=zh_cn&edition=full","pubTime":"2026-01-27 10:18","pubTimestamp":1769480299,"startTime":"0","endTime":"0","summary":"每经AI快讯，维立志博-B(09887.HK)涨超5%，截至发稿涨5.07%，报62.2港元，成交额2440.12万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601273631843738.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601273631843738.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000500386.USD","BK1161","HK0000252152.HKD","09887","HK0000252160.HKD"],"gpt_icon":0},{"id":"2606373574","title":"维立志博-B再涨超6% 维利信获欧盟孤儿药资格及美国FDA快速通道资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2606373574","media":"智通财经","labels":["shareholding","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606373574?lang=zh_cn&edition=full","pubTime":"2026-01-27 10:15","pubTimestamp":1769480134,"startTime":"0","endTime":"0","summary":"维立志博-B再涨超6%，截至发稿，涨5.07%，报62.2港元，成交额2440.12万港元。消息面上，维立志博1月22日宣布，核心产品维利信获欧盟委员会授予的孤儿药资格认定，用于治疗肺外神经内分泌癌。值得注意的是，1月14日，维利信获美国FDA授予快速通道资格认定，用于治疗肺外神经内分泌癌。维利信是一种同时靶向PD-L1与4-1BB的双特异性抗体，为针对肺外神经内分泌癌的全球首款达到注册临床阶段的靶向4-1BB受体的疗法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127103255a6b0e6f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127103255a6b0e6f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000500386.USD","BK1161","HK0000252152.HKD","HK0000252160.HKD","09887"],"gpt_icon":0},{"id":"2606329296","title":"港股异动 | 维立志博-B(09887)尾盘涨逾5% 双特异性抗体维利信获欧盟孤儿药认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2606329296","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606329296?lang=zh_cn&edition=full","pubTime":"2026-01-26 15:29","pubTimestamp":1769412554,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B早盘重挫后逐步转涨，尾盘涨幅扩大逾5%。截至发稿，涨5%，报58.85港元，成交额4573.08万港元。消息面上，维立志博宣布，核心产品维利信获欧盟委员会授予的孤儿药资格认定，用于治疗肺外神经内分泌癌。维利信是一种同时靶向PD-L1与4-1BB的抗体，已在中国的两项临床试验中显示出良好的疗效信号。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1397253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252152.HKD","09887","HK0000500386.USD","HK0000252160.HKD","FSXEmain","FESXmain","BK1161"],"gpt_icon":0},{"id":"2605404295","title":"维立志博-B01月23日主力净流入526.9万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2605404295","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605404295?lang=zh_cn&edition=full","pubTime":"2026-01-23 16:15","pubTimestamp":1769156123,"startTime":"0","endTime":"0","summary":"01月23日, 维立志博-B股价涨6.56%，报收56.05元，成交金额3214.1万元，换手率0.38%，振幅7.13%，量比2.34。维立志博-B今日主力资金净流入526.9万元，上一交易日主力净流出0万元。该股近5个交易日下跌0.80%，主力资金累计净流出610.1万元；近20日主力资金累计净流入642.4万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123161702a6a43130&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123161702a6a43130&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000252152.HKD","09887","HK0000500386.USD","HK0000252160.HKD","BK1161"],"gpt_icon":0},{"id":"2605260774","title":"港股异动 | 维立志博-B(09887)涨超5% 维利信™获欧盟委员会授予孤儿药认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2605260774","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605260774?lang=zh_cn&edition=full","pubTime":"2026-01-23 14:10","pubTimestamp":1769148617,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B(09887)涨超5%，截至发稿，涨4.94%，报55.2港元，成交额1800.35万港元。消息面上，1月22日，维立志博-B发布公告，于2026年1月22日，欧盟委员会(EC)发布关于PD-L1/4-1BB双特异性抗体维利信™(奥帕替苏米单抗，LBL-024)用于治疗肺外神经内分泌癌获授孤儿药认定的2026年1月9日委员会执行决定。这是继获得美国食品药品监督管理局(FDA)认定后，维利信™获得的第二项孤儿药认定，标志着维利信™在全球开发进程中的又一个重要里程碑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"港股异动 | 维立志博-B(09887)涨超5% 维利信™获欧盟委员会授予孤儿药认定","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000500386.USD","BK1161","HK0000252160.HKD","HK0000252152.HKD","BK1610","09887"],"gpt_icon":0},{"id":"2605997154","title":"维立志博-B(09887)：维利信™用于治疗肺外神经内分泌癌获欧盟委员会授予孤儿药认定（ODD）","url":"https://stock-news.laohu8.com/highlight/detail?id=2605997154","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605997154?lang=zh_cn&edition=full","pubTime":"2026-01-22 21:03","pubTimestamp":1769087010,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，于2026年1月22日，欧盟委员会发布关于PD-L1/4-1BB双特异性抗体维利信用于治疗肺外神经内分泌癌获授孤儿药认定的2026年1月9日委员会执行决定。这是继获得美国食品药品监督管理局认定后，维利信获得的第二项孤儿药认定，标志着维利信在全球开发进程中的又一个重要里程碑。根据EC的定义，孤儿药是拟用于诊断、预防或治疗危及生命或慢性衰弱性疾病且患病率在欧盟低于万分之五的药品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396366.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4183","HK0000500386.USD","HK0000252160.HKD","09887","ODD","IE0009354923.USD","BK1161","HK0000252152.HKD"],"gpt_icon":0},{"id":"2605266466","title":"板块跳水叠加基石解禁，维立志博-B(09887)何以吸引即将到来的北水资金？","url":"https://stock-news.laohu8.com/highlight/detail?id=2605266466","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605266466?lang=zh_cn&edition=full","pubTime":"2026-01-22 16:40","pubTimestamp":1769071203,"startTime":"0","endTime":"0","summary":"然而，维立志博此次重磅公告披露似乎并未得到相应关注。板块“跳水”叠加基石解禁，观望情绪主导市场1月15日，随着JPM大会的落幕，港股医药板块也在充分定价各种会议利好后，进入了利好兑现期。在6个月的限售期过后，维立志博将在今年1月25日迎来基石解禁日。今年1月14日，LBL-024获美国FDA授予快速通道资格认定，用于治疗肺外神经内分泌癌。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396149.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","BK1161","09887","HK0000500386.USD","HK0000252152.HKD"],"gpt_icon":0},{"id":"2605844500","title":"每日卖空追踪 | 维立志博-B 01月22日卖空量成交4000股，卖空比例为2.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605844500","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605844500?lang=zh_cn&edition=full","pubTime":"2026-01-22 16:30","pubTimestamp":1769070642,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间01月22日，涨2.63%，卖空量成交4000股，较上一交易日减少88.17%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122163852a69fcce3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122163852a69fcce3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000252160.HKD","09887","HK0000500386.USD","HK0000252152.HKD","BK1161"],"gpt_icon":0},{"id":"2605667194","title":"华福证券：首次覆盖维立志博(09887)给予“买入”评级 下一代IO和ADC疗法全布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2605667194","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605667194?lang=zh_cn&edition=full","pubTime":"2026-01-22 15:38","pubTimestamp":1769067529,"startTime":"0","endTime":"0","summary":"首次覆盖维立志博给予“买入”评级，预计维立志博2025-2027年营业收入分别为1.80、0.94、0.10亿元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260122/20260122154150_41671.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260122/20260122154150_41671.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["161027","09887","ADC"],"gpt_icon":0},{"id":"2603982879","title":"每日卖空追踪 | 维立志博-B 01月16日卖空量成交7600股，卖空比例为3.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603982879","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603982879?lang=zh_cn&edition=full","pubTime":"2026-01-16 16:30","pubTimestamp":1768552242,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间01月16日，涨1.44%，卖空量成交7600股，较上一交易日减少41.98%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116164226a4cb3ee0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116164226a4cb3ee0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161","HK0000252152.HKD","HK0000500386.USD","HK0000252160.HKD"],"gpt_icon":0},{"id":"2603662799","title":"维立志博-B01月16日主力净流入148.4万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2603662799","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603662799?lang=zh_cn&edition=full","pubTime":"2026-01-16 16:15","pubTimestamp":1768551334,"startTime":"0","endTime":"0","summary":"01月16日, 维立志博-B股价涨1.44%，报收56.50元，成交金额1463.6万元，换手率0.17%，振幅3.86%，量比0.57。维立志博-B今日主力资金净流入148.4万元，上一交易日主力净流出28.5万元。该股近5个交易日上涨0.89%，主力资金累计净流出211.3万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1167.7万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116161839a72216f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116161839a72216f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","HK0000500386.USD","HK0000252152.HKD","HK0000252160.HKD","09887"],"gpt_icon":0},{"id":"2603621919","title":"港股异动 | 维立志博-B(09887)涨超4% PD-L1/4-1BB双抗获FDA快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2603621919","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603621919?lang=zh_cn&edition=full","pubTime":"2026-01-15 10:02","pubTimestamp":1768442529,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B涨超4%，截至发稿，涨4.26%，报56.3港元，成交额300.03万港元。消息面上，1月14日晚，维立志博宣布，公司自主研发的抗PD-L1/4-1BB双特异性抗体维利信获得美国食品药品监督管理局授予快速通道资格认定，用于治疗肺外神经内分泌癌。这一里程碑将有力推动其全球开发进程，加速药物上市，早日惠及全球患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393120.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169589451.USD","BK4023","HK0000252160.HKD","BK1161","HK0000252152.HKD","09887","PD","HK0000500386.USD","LU1169590202.USD"],"gpt_icon":0},{"id":"2603157617","title":"港股公告掘金 | 东曜药业-B获药明合联溢价约99%提现金要约 1月15日复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2603157617","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603157617?lang=zh_cn&edition=full","pubTime":"2026-01-14 23:05","pubTimestamp":1768403110,"startTime":"0","endTime":"0","summary":"重大事项：龙旗科技(09611)1月14日至1月19日招股 拟全球发售5225.91万股H股和黄医药(00013)宣布SACHI III期研究结果于《柳叶刀 (The Lancet)》发表东阳光药(06887)推出面向PROTAC机制的AI智能研发平台 持续深化AI战略布局东曜药业-B(01875)获药明合联(02268)溢价约99%提现金要约 1月15日复牌维立志博-B(09887)：维利信(P","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252152.HKD","HK0000500386.USD","06030","BK1564","BK1191","BK1161","01875","00998","LU1497733631.SGD","LU2488822045.USD","LU1634259557.SGD","LU0572939691.SGD","BK1516","02268","LU0572940350.SGD","SG9999014674.SGD","LU0210526637.USD","06887","LU0051755006.USD","LU0264606111.USD","LU0456827905.SGD","LU1497734951.SGD","HK0000252160.HKD","BK1141","LU1497733557.USD","09887","BK1231","BK1521","LU1634259391.SGD","BK1560","LU1522347837.USD","LU1720050803.USD","BK1574","BK1147","LU1794554557.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.leadsbiolabs.com","stockEarnings":[{"period":"1week","weight":0.0756},{"period":"1month","weight":0.3099},{"period":"3month","weight":0.175},{"period":"6month","weight":-0.065},{"period":"1year","weight":0.89},{"period":"ytd","weight":0.2971}],"compareEarnings":[{"period":"1week","weight":-0.0108},{"period":"1month","weight":0.0188},{"period":"3month","weight":0.0347},{"period":"6month","weight":0.0699},{"period":"1year","weight":0.3273},{"period":"ytd","weight":0.047}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"南京维立志博生物科技股份有限公司是一家主要从事发现、开发和商业化治疗肿瘤、自身免疫性疾病以及其他严重疾病的新疗法的中国公司。该公司的主要候选药物包括LBL-024、LBL-034、LBL-033、LBL-007等。该公司的LBL-024主要用于治疗肺外神经内分泌癌（EP-NEC）、小细胞肺癌（SCLC）、胆道癌（BTC）及非小细胞肺癌（NSCLC）、食管鳞状细胞癌（ESCC）、肝细胞癌（HCC）、胃癌（GC）及其他实体瘤。该公司还开发了专有技术平台，包括LeadsBody平台（CD3 T-cell engager平台）、X-body平台（4-1BB engager平台）以及其他几个双特异性抗体及融合蛋白平台。该公司主要在国内市场开展业务。","exchange":"SEHK","name":"维立志博-B","nameEN":"LEADS BIOLABS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"维立志博-B,09887,维立志博-B股票,维立志博-B股票老虎,维立志博-B股票老虎国际,维立志博-B行情,维立志博-B股票行情,维立志博-B股价,维立志博-B股市,维立志博-B股票价格,维立志博-B股票交易,维立志博-B股票购买,维立志博-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}